ADC Therapeutics SA 8-K

What Happened

• ADC Therapeutics SA (Nasdaq: ADCT) filed a Current Report on Form 8-K on June 3, 2026 to disclose information under Regulation FD (Item 7.01) and Other Events (Item 8.01).
• The filing furnishes a press release dated June 3, 2026 (Exhibit 99.1) and an investor presentation dated June 3, 2026 (Exhibit 99.2). The interactive cover page XBRL file is included as Exhibit 104.

Key Details

• Filing date: June 3, 2026 (SEC Accession No. 0000950103-26-008465).
• Exhibits furnished: 99.1 (press release), 99.2 (presentation), and 104 (Cover Page Interactive Data File).
• Disclosure was made under Item 7.01 (Regulation FD) and Item 8.01 (Other Events) of Form 8-K.
• The filing furnishes information to the public; it does not, by itself, attach audited financial statements or report executive changes.

Why It Matters

• Regulation FD disclosures are intended to ensure material information is shared broadly and simultaneously, so investors should review the attached press release and presentation to see what the company publicly disclosed on June 3, 2026.
• The exhibits may contain operational, clinical, or strategic updates important for assessing ADCT’s near-term outlook; investors should read Exhibits 99.1 and 99.2 on the SEC EDGAR site or the company website for specifics.
• This Form 8-K does not replace other filings that would report quarterly results or formal financial statements—watch for subsequent filings (e.g., 10-Q, 10-K) for detailed earnings or revenue disclosures.